张聪;韩丹丹;陈成军;黄浩;唐星;
ZHANG Cong,HAN Dan-dan,CHEN Cheng-jun,HUANG Hao,TANG Xing(School of Pharmacy,Shenyang pharmaceutical University,Shenyang 110016,China)

• 1:沈阳药科大学药学院

摘要(Abstract)：

目的湿法研磨结合挤出滚圆法制备稳定性良好的非诺贝特骨架型缓释微丸。方法将微粉化非诺贝特与亲水性载体共研磨,研磨液用固体辅料吸收,通过挤出滚圆法制备缓释微丸。以制剂体外释放度及加速试验中制剂稳定性为指标,筛选了研磨混悬液中亲水性载体的种类,考察了微晶纤维素用量、乳糖用量、挤出次数、滚圆时间等对药物释放的影响。结果以质量浓度为0.1 kg.L-1聚维酮(K30)为亲水载体溶液,药物与载体质量之比为10∶1时,制备微丸的释放度符合中国卫生部颁发标准(1 h释放10%³0%;4 h释放50%30%;4 h释放50%⁷5%;7 h释放75%以上),体外释药过程符合Higuchi方程。结论成功地制备了非诺贝特骨架型缓释微丸,该制备工艺重现性好,具有理想的缓释效果,加速试验稳定性良好。
Objective To investigate the preparation and storage stability of the fenofibrate matrix sustained release pellets by wet milling and extrusion-spheronization.Methods Suspension of micronized fenofibrate with hydrophilic vehicle solution was prepared by wet milling technology in a mill,and then fenofibrate pellets was prepared by extrusion-spheronization process.The release properties and storage stability of the preparation were investigated to select the best vehicle.Several factors that affected the sustained release characteristics,such as the amounts of MCC and lactose,times of extrusion,spheronization time were assessed.Results 0.1 kg·L-1polyvidone(K30) was applied to hydrophilic vehicle,the ratio of fenofibrate to vehicle was 10∶1,prepared stable fenofibrate pellets,release of the fenofibrate from pellets was in accordance with Higuchi equation.Conclusions Combined wet milling technology with extrusion-spheronization process,good and stable fenofibrate matrix sustained-release pellets can be prepared.

关键词(KeyWords)： 非诺贝特;骨架型缓释微丸;挤出滚圆;湿法研磨;聚维酮(K30)
fenofibrate;matrix sustained-release pellets;extrusion-spheronization;wet milling;polyvidone(K30)

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 张聪;韩丹丹;陈成军;黄浩;唐星;
ZHANG Cong,HAN Dan-dan,CHEN Cheng-jun,HUANG Hao,TANG Xing(School of Pharmacy,Shenyang pharmaceutical University,Shenyang 110016,China)

DOI: 10.14066/j.cnki.cn21-1349/r.2010.05.019

参考文献(References)：

• [1]徐帆,冯恩富,余昉.HPLC法测定血浆中非诺贝特活性代谢物非诺贝酸的浓度[J].中国药师,2007,10(6):530-532.
• [2]VOGE M,KUNATH K,DRESSMAN J B.Dissolutionenhancement of fenofibrate by micronization,cogrindingand spray-drying:Comparison with commercial prepara-tions[J].European Journal of Pharmaceutics and Biop-harmaceutics,2008,68(2):283-288.
• [3]SHEPHERD J.The fibrates in clinical practice:focus onmicronised fenofibrate[J].Atherosclerosis,1994,110(Suppl 1):S55-S63.
• [4]徐月红,王宁生.中药微粉化的现状与分析[J].中国中药杂志,2004,29(6):497-500.
• [5]AGUIAR A J,ZELMER A W,KINKEL A W.Deag-gregation behavior of a relatively in soluble substitutedbenzoic acid and its sodium salt[J].Journal of Pharma-ceutical Sciences,1967,56(10):1243-1252.
• [6]FINHOLTP,SLOVANG S.Dissolution kinetics of drugsin human gastric juice the role of surface tension[J].Journal of Pharmaceutical Sciences,1968,57(8):1322-1326.